| Bioactivity | BI 639667 (compound 19n), a third azaindazole series compound, is a CCR1 antagonist, with an IC50 of 1.8 nM in Ca2+ flux assay[1]. | ||||||||||||
| Name | BI 639667 | ||||||||||||
| CAS | 1295298-26-8 | ||||||||||||
| Formula | C22H18FN5O3S | ||||||||||||
| Molar Mass | 451.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Harcken C, et al. Identification of novel azaindazole CCR1 antagonist clinical candidates. Bioorg Med Chem Lett. 2019 Feb 1;29(3):441-448. |
BI 639667
CAS: 1295298-26-8 F: C22H18FN5O3S W: 451.47
BI 639667 (compound 19n), a third azaindazole series compound, is a CCR1 antagonist, with an IC50 of 1.8 nM in Ca2+ flux
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.